

1 **Title: Hepatitis E in Kathmandu Valley: Insights from a Representative Longitudinal**
2 **Serosurvey**

3

4 **Authors**

5 Nishan Katuwal^{1,2}, Melina Thapa¹, Sony Shrestha¹, Krista Vaidya^{1,3}, Isaac I Bogoch⁴,
6 Jason Andrews⁵, Rajeev Shrestha^{1,2}, Dipesh Tamrakar^{1,2,6¥}, Kristen Aiemjoy^{3,7¥*}

7

8 1 Research and Development Division, Dhulikhel Hospital, Kathmandu University
9 Hospital, Nepal

10 2 Center for Infectious Disease Research and Surveillance, Dhulikhel Hospital,
11 Kathmandu University Hospital, Nepal

12 3 Division of Epidemiology, Department of Public Health Sciences, University of California
13 Davis School of Medicine, USA

14 4 Department of Medicine, University of Toronto, Canada

15 5 Division of Infectious Diseases and Geographic Medicine, Stanford University School
16 of Medicine, USA

17 6 Department of Community Medicine, Kathmandu University School of Medical
18 Sciences, Nepal

19 7 Department of Microbiology and Immunology, Mahidol University Faculty of Tropical
20 Medicine, Thailand

21

22 ***Corresponding Author:**

23 Dr. Kristen Aiemjoy

24 Email: kaiemjoy@ucdavis.edu

25

26 ¥: equal contribution

27

28

29

30 **ABSTRACT**

31

32 Hepatitis-E virus (HEV), an etiologic agent of acute inflammatory liver disease, is a
33 significant cause of morbidity and mortality in South Asia. HEV is considered endemic in
34 Nepal; but data on population-level infection transmission is sparse. We conducted a
35 representative longitudinal serologic study between February 2019 and April 2021 in
36 urban and peri-urban areas of central Nepal to characterize community-level HEV
37 transmission. Individuals were followed up to four times, during which capillary blood
38 samples were collected on dried blood spots and tested for anti-HEV immunoglobulin-G
39 antibodies. Analyzing 2513 dried blood samples from 923 participants aged 0-25 years,
40 we found a seroprevalence of 4.8% and a seroincidence rate of 10.9 per 1000 person-
41 years. Notably, young adults, including women of childbearing age, faced the highest
42 incidence of infection. Geospatial analysis identified potential HEV clusters in Kavre and
43 Kathmandu districts, emphasizing the need for targeted interventions. Water source
44 played a crucial role in HEV transmission, with individuals consuming surface water facing
45 the highest risk of seroconversion. Our findings underscore the endemic nature of HEV
46 in Nepal, emphasizing the importance of safe water practices and potential vaccination
47 strategies for high-risk groups.

48

49

50

51

52

53

54

55

56

57 **BACKGROUND**

58 Hepatitis E Virus (HEV), first identified in 1983, has emerged as the leading cause of
59 acute clinical hepatitis in South Asia (1). The overall mortality rate associated with HEV
60 is 1–4% (2). Immunocompromised individuals and pregnant women face the highest risk
61 for complications and death, with mortality rates reaching up to 20% among pregnant
62 women in their third trimester (3). The virus is primarily transmitted through food and water
63 contaminated with infected fecal material, disproportionately affecting individuals in
64 locations lacking improved sanitation systems (2).

65 HEV is estimated to cause approximately 20 million new infections annually, leading to
66 around 3.3 million symptomatic cases and 70,000 deaths (4). However, these figures may
67 be underestimates due to limited surveillance capacity and suboptimal access to
68 laboratory diagnostics, which often leave many infections, especially pauci-symptomatic
69 and subclinical cases, undetected and under-reported (5).

70 Sero-epidemiology provides a valuable tool to augment clinical surveillance of HEV,
71 particularly when diagnostics and reporting systems are limited (6). Population-level sero-
72 responses also offers insights into exposure that are not biased by access to health care
73 and care-seeking behaviors (7). Despite the existence of four recognized HEV genotypes,
74 the antibody responses they elicit are similar (2). IgG antibody responses peak 2–6 weeks
75 post-infection (8,9) then start to decay. A study of confirmed HEV patients in Nepal found
76 that IgG responses decayed substantially in the first 6 months but remained elevated
77 above a seropositivity threshold for at least 14 months (10).

78 Nepal, considered endemic for hepatitis E virus, has experienced repeated outbreaks of
79 HEV with sporadic cases of acute hepatitis between such outbreaks (11). A study among
80 individuals seeking orthopedic care in Kathmandu between 2010 and 2012 found an IgG
81 seroprevalence of 47.1% (12). Among healthy blood donors in Kathmandu in 2014, the
82 age-adjusted seroprevalence of HEV was 3.2% for IgM and 8.3% for IgG (13). A study
83 conducted after the 2015 earthquake among blood donors residing in earthquake-
84 affected areas found a HEV seroprevalence of 3.2% for IgM and 41.9% for IgG (14). Most
85 previous seroprevalence studies were conducted using convenience samples (healthy

86 blood donors or individuals seeking care in a hospital setting), and it is unknown how well
87 these estimates represent the general population .

88 To meet this gap, we performed a longitudinal HEV serosurvey among a geographically
89 random population-based sample of children and young adults residing in Kathmandu
90 and Kavre districts. The aim was to gain a better understanding of the geographic
91 distribution of HEV, characterize the incidence, and investigate risk factors related to
92 exposure.

93 **METHODS**

94 **Overview**

95 We conducted a representative, population-based longitudinal cohort study in urban
96 (Kathmandu) and peri-urban (Kavre) areas of Nepal to characterize community-level HEV
97 incidence. We enrolled geographically random sample of individuals aged 0-25 years
98 from the catchment areas of Kathmandu Medical College in Kathmandu and Dhulikhel
99 Hospital in Kavrepalanchok, Nepal from Feb 2019 to Apr 2021(15). Participants were
100 followed-up three times, approximately 3 months, 6 months, and 12 months after initial
101 enrollment and consent. During enrollment, relevant demographic data including age,
102 sex, socioeconomic status, were collected.

103 **Sampling method**

104 We employed a systematic random sampling strategy within our defined catchment
105 areas. We randomly selected grid clusters, enumerated all households within each
106 cluster, and then randomly selected participants based on age stratification using the
107 groups 0-4, 5-9, 10-15, and 16-25 years. Our exclusion criteria were minimal to ensure a
108 representative sample. We only excluded individuals who were not residents of the
109 catchment area or did not fall within our specified age range at the time of the cross-
110 sectional survey.

111

112

113 **Sample collection**

114 At each visit, we collected capillary blood samples onto filter papers (TropBio FP 05-002-
115 12) using a finger-prick (dried blood spots; DBS). The samples were dried at room
116 temperature for 24 hours then stored in individual plastic bags with desiccant at -20 C.

117 **Laboratory Methods**

118 We eluted the dried blood spots by submerging a single filled filter paper protrusion in
119 133 μ L of 1X PBS containing 0.05% Tween buffer and incubating overnight at 4°C. We
120 then centrifuged the tubes at 10,000xg and aliquoted the supernatant, considering this
121 DBS eluate as a 1:10 dilution.

122

123 We analyzed the samples using end-point ELISA with recomWell HEV IgG ELISA kits
124 (Mikrogen Diagnostik), which evaluate immunoglobulin IgG against the recombinant
125 HEV-ORF2 antigen. We read the ELISA plates at a wavelength of 450nm (with a
126 reference wavelength of 690nm) using a Bio-Rad iMark ELISA plate reader.

127 **Statistical Analysis**

128

129 We fit 2-component Gaussian finite mixture models to determine an optimal cutoff value,
130 defined as the mean plus 3.5 standard deviations from the lower mixture component of
131 the log-transformed values (16). We then calculated seroprevalence as the percentage
132 of samples that were seropositive at each sampling interval. To describe how
133 seropositivity changes over age, we fit generalized additive models with a cubic spline for
134 age (17). We computed simultaneous confidence intervals using a parametric bootstrap
135 of the variance-covariance matrix of the fitted model parameters (18) (Mara, 2012). To
136 investigate variables associated with seropositivity, we used mixed-effect binomial logit
137 models with a random effect for community (19).

138

139 We calculated seroincidence, defined as the number of new seroconversions per 1000
140 person years, by dividing the number of individuals who seroconverted by the person-
141 time at risk between measurements. We defined incident seroconversions as a change

142 in IgG across the seropositivity cutoff between sampling intervals. We used negative
143 binomial mixed-effects regression models to explore the influence of various predictors
144 on seroincidence, including area, gender, income level, water source, and frequency of
145 eating outside, while adjusting for age. Each predictor was individually incorporated into
146 the model, which also accounted for repeated measurements on the same individual
147 across different visits and individual-level variability. An offset was introduced to adjust
148 for person-time.

149

150 **Ethical Considerations**

151 The study protocol was reviewed and approved by the Nepal Health Research Council
152 and Ethics Review Board of Dhulikhel Hospital and Stanford University. Written informed
153 consent was obtained from all participants or their parents or legal guardians in the case
154 of minors age <18. In addition, we obtained written assent from children between the ages
155 of 15 and 17. The study was conducted following the principles of the Declaration of
156 Helsinki.

157 **RESULTS**

158 We collected a total of 2513 dried blood samples from 923 study participants between
159 February 2019 to April 2021. Out of 923 study participants, 401 were from Kathmandu,
160 197 from Panauti (Kavre), 167 from Banepa (Kavre), 85 from Dhulikhel (Kavre) and 73
161 from Panchkhal (Kavre). The median age of participants was 11 years (Inter Quartile
162 Range [IQR]: 5.6 - 17) and 52.2% (482/923) were male. The median number of study
163 visits completed was 3 (IQR 2-3); 229/923; 65% (603/923) of participants had 3 or more
164 study visits while 18.2% 168/923 had just 1 study visit and 16.4% 152/923 had 2 study
165 visits (Table 1).

166

167 From the total of 2513 processed samples from 923 enrolled individuals, 106 samples
168 (53 individuals) were seropositive for HEV (Figure 1). At the baseline visit, the crude
169 seroprevalence was 4.8% (44/923) (Table 2). There were 9 incident seroconversions over

170 822.8 years of person-time, yielding a crude seroincidence rate of 10.9 (95% CI 5-20.8)
171 per 1000 person-years (Table 3). Both seroprevalence and seroincidence increased with
172 age. Among 0-5 year olds, the seroprevalence was 1.0% (2/199), increasing to 11.1%
173 (33/297) in the 15 to 25-year-old age group ($p = 0.001$; see Table 2 and Figure 2). The
174 seroincidence rate rose from 0 (95%CI: 0 - 32) per 1000 person-years for 0 to 5 year-olds
175 to 9.0 (95%CI: 1 - 32.4) for 5 to 10 year-olds, 14.0 (95%CI: 2.9 - 40.8) for 10 to 15 year-
176 olds, and 14.8 (95%CI: 4.0 - 37.9) for 15 to 25 year-olds (Table 3). The age-adjusted
177 seroincidence was similar among females (10.3, 95% CI 2.8 - 26.3) compared to males
178 (11.6, 95% CI 3.8 - 27.2) (Table 3).

179
180 Individuals residing in households with a monthly income exceeding 30,000 Nepalese
181 rupees had a HEV seroprevalence of 4.3% (95% CI 2.5 - 7.5) compared to 1.4% (95% CI
182 0.7-3.0) for those in households earning below 30,000 Nepalese rupees ($p = 0.003$). The
183 age-adjusted seroincidence rate for the higher income group was 9.4 (95% CI 3.0 - 30.0)
184 per 1000 person years, and 7.5 (95% CI 2.4-23.3) for the lower income group.

185
186 HEV seroprevalence estimates did not vary markedly according to drinking water source,
187 with a seroprevalence of 2.9% (95% CI 1.3-6.3) among individuals whose primary
188 drinking water source was surface water, 3.6% (95% CI 1.9 - 6.6) for bottled water, 1.9%
189 (95%CI: 0.9-3.9) for municipal water, 2.3% (95%CI: 0.9-5.8) for ground water and 0.8%
190 (95%CI: 0.1-6.3) for a private water company. However, the HEV seroincidence rate
191 among individuals drinking surface water was higher than the other groups at 24.8
192 (95%CI: 9.9 – 61.5) per 1000 person-years compared to 5.6 (95% CI: 1.4-22.8) for
193 municipal water ($p = 0.076$). Of the 9 incident seroconversions, 5 reported drinking
194 surface water and of these 3 did not treat, 1 treated sometimes (<50% of the time) and 1
195 reported always treated water by boiling. However, when aggregated there were no
196 differences in HEV seroprevalence or seroincidence according to whether the household
197 treated their drinking water or not. Detailed seroprevalence and seroincidence are
198 provided in Tables 2 and 3.

199 HEV seroprevalence and seroincidence were not geographically uniform. The
200 seropositive cases are geospatially represented in Figure 2, revealing potential clusters

201 in both Kavre and Kathmandu districts. In Kavre district, seroprevalence was highest in
202 Banepa 3.5% (95% CI 1.7-7.3) and Panchkal 3.6% (95% CI 1.3-9.9). Within
203 Kathmandu, seropositive cases were centered in south-west of Tribhuvan airport, the one
204 incidence seroconversion was also in this area. In Kavre, seroconversions were centered
205 near Banepa (Figure 2).

206 **DISCUSSION**

207 This representative longitudinal serosurvey reveals ongoing HEV exposure in the
208 Kathmandu Valley of Nepal. With a total of 2513 dried blood samples collected from 923
209 children and young adults, we observed a seroprevalence of 4.8% and a seroincidence
210 rate of 10.9 seroconversions per 1000 person-years. These findings are consistent with
211 the growing body of evidence suggesting that HEV is endemic in many parts of Nepal
212 (10,11,13,14,20).

213

214 Unlike many enteric infections where the youngest are at the highest risk, our study found
215 the highest seroincidence among adolescents and young adults. Among those aged 15-
216 25, 1 in 10 participants had evidence of HEV IgG exposure. This age group is particularly
217 significant as it encompasses women of childbearing age, where the risks of HEV
218 complications and mortality peak (3). This aligns with findings from other studies in
219 Bangladesh (6) and Nepal (20), which reported the highest HEV seroprevalence among
220 oldest enrolled subjects (70-74 in Bangladesh and 30-39 in Nepal). However, with
221 seroprevalence, these other studies were limited in their ability to disentangle age and
222 cohort effects. It's possible that seroprevalence among older ages reflected higher
223 periods of exposure in the past. In this study, by measuring incident seroconversions, we
224 were able to characterize a genuine higher risk of exposure with age.

225

226 The clustering of seropositive cases, especially around Banepa in Kavre and the
227 southwestern region of Tribhuvan airport in Kathmandu, suggests localized outbreaks or
228 common sources of exposure. The majority of incidence seroconversions in Kavre were
229 within five kilometers of Banepa – where a high seroprevalence was observed at baseline.
230 This may suggest propagative transmission from a potential previous outbreak. Such

231 clustering has been observed in other studies (21, 22), and underscores the importance
232 of targeted public health interventions in these regions.

233
234 Water source emerged as a significant factor influencing HEV seroincidence. Individuals
235 consuming surface water exhibited a notably higher seroincidence rate compared to
236 those relying on other water sources. This finding aligns with previous studies that have
237 identified contaminated water as a primary transmission route for HEV (21,22). The fact
238 that a majority of the incident seroconversions were observed in individuals who
239 consumed untreated or occasionally treated surface water further underscores the
240 importance of water quality in HEV exposure. The spread of HEV to the environment might
241 pollute surface waters, which could act as the source of infection for both humans and
242 animals (23). Moreover, the occurrence of HEV in different water environments, even in
243 industrialized countries with sanitation and safe water supplies, has been documented,
244 emphasizing the need for continuous monitoring and intervention (23).

245
246 This study stands out as one of the few representative longitudinal serosurveys
247 specifically designed to capture incidence HEV seroconversions alongside HEV
248 seroprevalence. The variability in seroprevalence estimates across studies, even within
249 identical regions, is well-documented (24). Some of these discrepancies can be attributed
250 to methodologies that overlook the age-dependent nature of seroprevalence and/or
251 ignore antibody decay. Ignoring the waning of antibodies can lead to underestimations of
252 both seroprevalence and seroincidence, contingent on the rate and pattern of antibody
253 decay (25). In our study, the seroincidence derived from the age-dependent cross-
254 sectional visit underestimated the true seroincidence by half. Moreover, seroincidence
255 measures are particularly valuable in identifying recent exposures that could amplify the
256 risk of infection and in pinpointing outbreaks. As an illustration, in our study while there
257 were only minor differences in seroprevalence based on water source, the seroincidence
258 of HEV among individuals consuming surface water was more than quadruple that of
259 those drinking municipal water.

260

261 Several limitations are worth noting. Firstly, our cohort did not include individuals above
262 25 years of age, restricting our ability to comment on the HEV burden in older age groups.
263 However, prior research has indicated that the most significant HEV burden is among
264 young adults(6,20). Our use of dried blood samples, though logistically advantageous,
265 might have increased the limit of detection our serological assays. A recent study
266 comparing HEV IgG responses in dried blood spots to venous blood reported a sensitivity
267 of 81% and a specificity of 97% (26). Given this reduced sensitivity, our findings may
268 underestimate the true HEV seroprevalence and seroincidence by up to 20%.
269 Additionally, our household sampling strategy could have inadvertently omitted migrant
270 populations and residents of informal settlements. Such populations, often faced with
271 subpar water, sanitation, and hygiene conditions, could potentially have a higher HEV
272 seropositivity rate, potentially further biasing our findings towards the null.

273

274 In summary, our study underscores the endemic nature of HEV in Nepal, revealing
275 significant variations in seroprevalence and seroincidence based on age, water source,
276 and geography. These insights emphasize the urgency for targeted public health
277 strategies, especially in identified clusters, and spotlight the critical role of safe water
278 practices in curtailing HEV incidence.

279

280 **Acknowledgments**

281 We gratefully acknowledge the study participants for their valuable time and interest in
282 participating in the studies.

283

284

285

286

287

288

289 **Tables**

290 **Table 1: Demographic Characteristics of enrolled individuals**

	Banepa (N=167)	Dhulikhel (N=85)	Kathmandu (N=401)	Panauti (N=197)	Panchkhal (N=73)	Overall (N=923)
Age, in years						
Median (IQR)	10 (5.3 - 16)	9.5 (5.4 - 15)	12 (6.0 - 18)	11 (4.8 - 17)	10 (5.7 - 16)	11 (5.6 - 17)
Min/Max	1.2 - 27	1.1 - 25	0.90 - 27	0.90 - 27	1.3 - 24	0.90 - 27
Gender						
Female	82 (49.1%)	41 (48.2%)	183 (45.6%)	92 (46.7%)	33 (45.2%)	431 (46.7%)
Male	83 (49.7%)	43 (50.6%)	214 (53.4%)	102 (51.8%)	40 (54.8%)	482 (52.2%)
Missing	2 (1.2%)	1 (1.2%)	4 (1.0%)	3 (1.5%)	0 (0%)	10 (1.1%)
Number of study visits						
Median (IQR)	3.0 (3.0 - 4.0)	4.0 (3.0 - 4.0)	2.0 (1.0 - 3.0)	3.0 (2.0 - 4.0)	3.0 (3.0 - 3.0)	3.0 (2.0 - 3.0)
Min/Max	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0
Monthly income, Nepalese rupees						
< 15000	11 (6.6%)	13 (15.3%)	34 (8.5%)	30 (15.2%)	12 (16.4%)	100 (10.8%)
15000-30000	47 (28.1%)	26 (30.6%)	116 (28.9%)	94 (47.7%)	29 (39.7%)	312 (33.8%)
30000-50000	49 (29.3%)	23 (27.1%)	119 (29.7%)	33 (16.8%)	13 (17.8%)	237 (25.7%)
>50000	17 (10.2%)	8 (9.4%)	55 (13.7%)	9 (4.6%)	6 (8.2%)	95 (10.3%)
Missing	43 (25.7%)	15 (17.6%)	77 (19.2%)	31 (15.7%)	13 (17.8%)	179 (19.4%)
Primary water source						
Municipal	88 (52.7%)	75 (88.2%)	116 (28.9%)	34 (17.3%)	13 (17.8%)	326 (35.3%)
Bottled	33 (19.8%)	0 (0%)	210 (52.4%)	0 (0%)	3 (4.1%)	246 (26.7%)
Ground	5 (3.0%)	2 (2.4%)	27 (6.7%)	55 (27.9%)	40 (54.8%)	129 (14.0%)
Private	4 (2.4%)	0 (0%)	36 (9.0%)	0 (0%)	0 (0%)	40 (4.3%)
Surface	35 (21.0%)	7 (8.2%)	7 (1.7%)	105 (53.3%)	17 (23.3%)	171 (18.5%)
Missing	2 (1.2%)	1 (1.2%)	5 (1.2%)	3 (1.5%)	0 (0%)	11 (1.2%)
Treat water before drinking						
No	65 (38.9%)	58 (68.2%)	190 (47.4%)	109 (55.3%)	50 (68.5%)	472 (51.1%)
Yes	100 (59.9%)	26 (30.6%)	206 (51.4%)	85 (43.1%)	23 (31.5%)	440 (47.7%)
Missing	2 (1.2%)	1 (1.2%)	5 (1.2%)	3 (1.5%)	0 (0%)	11 (1.2%)

291

292

293

294

295

296

297 Table 2: HEV Seroprevalence at baseline visit

levels	N()	N seropositive	Crude seroprevalence	Modeled seroprevalence (95% CI)	p value
Overall	923	44	4.8%	•	•
Age, categorical					
0-<5	199	2	1.0%	1.0% (0.3-3.9)	•
5-<10	204	2	1.0%	1.0% (0.2-3.8)	0.980
10-<15	223	7	3.1%	3.1% (1.5-6.4)	0.151
15-25	297	33	11.1%	11.1% (8.0-15.2)	0.001
City/town*					
Banepa	167	10	6.0%	3.5% (1.7-7.3)	Ref
Dhulikhel	85	1	1.2%	0.7% (0.1-5.3)	0.139
Kathmandu	401	19	4.7%	2.3% (1.2-4.1)	0.279
Panauti	197	10	5.1%	2.7% (1.3-5.7)	0.583
Panchkhal	73	4	5.5%	3.6% (1.3-9.9)	0.973
Gender*					
Female	431	19	4.4%	2.4% (1.3-4.3)	Ref
Male	482	24	5.0%	2.7% (1.5-4.6)	0.725
Household monthly income, Nepalese rupees*					
<30000	412	10	2.4%	1.4% (0.7-2.9)	Ref
>30000	332	26	7.8%	4.3% (2.5-7.4)	0.003
Primary water source*					
Municipal	326	11	3.4%	1.9% (0.9-3.9)	Ref
Bottled	246	17	6.9%	3.6% (1.9-6.6)	0.119
Ground	129	5	3.9%	2.3% (0.9-5.8)	0.760
Private	40	1	2.5%	0.8% (0.1-6.3)	0.432
Surface	171	9	5.3%	2.9% (1.3-6.3)	0.368
Household treats drinking water*					
No	472	18	3.8%	2.1% (1.2-3.8)	Ref
Yes	440	25	5.7%	3.0% (1.7-5.1)	0.286

Note:

*Mixed effect models adjusted for age with a random effect for city/town

298

299

300 Table 3: HEV Seroincidence

	Incident seroconversions	Person-years	Seroincidence rate per 100,000 person-years		
			Seroconversions/person-time	Modeled seroincidence*	p-value*
Overall	9	822.8	10.9 (5.0-20.8)	10.3 (5.3-19.7)	•
Age, categorical					
0-<5	0	115.2	0.0 (0.0-32.0)	0.00 (0.00-0.31)	•
5-<10	2	222.7	9.0 (1.1-32.4)	8.73 (2.19-34.89)	Ref
10-<15	3	214.7	14.0 (2.9-40.8)	13.46 (4.34-41.71)	0.019
15-25	4	270.2	14.8 (4.0-37.9)	13.08 (4.91-34.84)	0.019
City/town*					
Banepa	2	170.5	11.7 (1.4-42.4)	10.5 (2.6-42.6)	Ref
Dhulikhel	2	106.9	18.7 (2.3-67.6)	17.1 (4.2-69.2)	0.625
Kathmandu	1	247.6	4.0 (0.1-22.5)	3.4 (0.5-24.5)	0.355
Panauti	4	208.9	19.1 (5.2-49.0)	16.8 (6.1-46.3)	0.588
Panchkhal	0	89.0	0.0 (0.0-41.4)	•	1.000
Gender*					
Female	4	389.8	10.3 (2.8-26.3)	8.9 (3.2-24.7)	Ref
Male	5	429.4	11.6 (3.8-27.2)	10.3 (4.2-25.5)	0.831
Household monthly income, Nepalese rupees*					
<30000	3	381.6	7.9 (1.6-23.0)	7.5 (2.4-23.3)	Ref
>30000	3	283.5	10.6 (2.2-30.9)	9.4 (3.0-30.0)	0.779
Primary water source*					
Municipal	2	320.7	6.2 (0.8-22.5)	5.6 (1.4-22.8)	Ref
Bottled	1	157.7	6.3 (0.2-35.3)	5.3 (0.7-38.2)	0.958
Ground	1	138.0	7.2 (0.2-40.4)	6.5 (0.9-46.8)	0.903
Private	0	26.1	0.0 (0.0-141.3)	•	1.000
Surface	5	176.7	28.3 (9.2-66.0)	24.8 (10.0-61.5)	0.076
Household treats drinking water*					
No	5	442.4	11.3 (3.7-26.4)	10.1 (4.1-24.9)	Ref
Yes	4	376.8	10.6 (2.9-27.2)	9.1 (3.3-25.3)	0.879

Note:


*Mixed effect poisson model adjusted for age and repeated measures

301

302

303 **Figures**

304 **Figure 1: Quantitative antibody responses by date and study site location**




305

306


307

308 Figure 2: Age-dependent Seroprevalence



309

310 Figure 3: HEV Seroprevalence at baseline and prospective seroconversions across the
311 enrollment areas (Banepa, Panauti, Dhulikhel, Panchkhal: Kavre and Kathmandu) and
312 over the enrollment period of Feb 2019 to Apr 2021



313

314 **REFERENCES**

- 315 1. Jindal A, Sarin SK. Epidemiology of liver failure in Asia-Pacific region. *Liver*
316 *International*. 2022;42(9):2093–109.
- 317 2. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E.
318 *The Lancet*. 2012 Jun 30;379(9835):2477–88.
- 319 3. Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding
320 the pathogenesis. *Liver International*. 2008;28(9):1190–9.
- 321 4. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of
322 hepatitis E virus genotypes 1 and 2 in 2005. *Hepatology*. 2012;55(4):988–97.
- 323 5. Aggarwal R, Naik S. Epidemiology of hepatitis E: Current status. *Journal of*
324 *Gastroenterology and Hepatology*. 2009;24(9):1484–93.
- 325 6. Azman AS, Paul KK, Bhuiyan TR, Koyuncu A, Salje H, Qadri F, et al. Hepatitis E in
326 Bangladesh: Insights From a National Serosurvey. *The Journal of Infectious*
327 *Diseases*. 2021 Dec 15;224(Supplement_7):S805–12.
- 328 7. Aiemjoy K, Seidman JC, Charles RC, Andrews JR. Seroepidemiology for Enteric
329 Fever: Emerging Approaches and Opportunities. *Open Forum Infectious Diseases*.
330 2023 May 1;10(Supplement_1):S21–5.
- 331 8. Kmush BL, Yu H, Huang S, Zhang X, Wu T, Nelson KE, et al. Long-term Antibody
332 Persistence After Hepatitis E Virus Infection and Vaccination in Dongtai, China. *Open*
333 *Forum Infect Dis*. 2019 Mar 28;6(4):ofz144.
- 334 9. Huang S, Zhang X, Jiang H, Yan Q, Ai X, Wang Y, et al. Profile of Acute Infectious
335 Markers in Sporadic Hepatitis E. *PLOS ONE*. 2010 Oct 21;5(10):e13560.
- 336 10. Myint KSA, Endy TP, Shrestha MP, Shrestha SK, Vaughn DW, Innis BL, et al.
337 Hepatitis E antibody kinetics in Nepalese patients☆. *Transactions of The Royal*
338 *Society of Tropical Medicine and Hygiene*. 2006 Oct 1;100(10):938–41.
- 339 11. Shrestha S. Hepatitis E in Nepal. *Kathmandu University medical journal (KUMJ)*. 2006
340 Oct 1;4:530–44.
- 341 12. Izopet J, Labrique AB, Basnyat B, Dalton HR, Kmush B, Heaney CD, et al. Hepatitis
342 E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and
343 southwest France. *Journal of Clinical Virology*. 2015 Sep 1;70:39–42.
- 344 13. Gupta BP, Lama TK, Adhikari A, Shrestha A, Rauniyar R, Sapkota B, et al. First report
345 of hepatitis E virus viremia in healthy blood donors from Nepal. *Virusdisease*. 2016
346 Sep;27(3):324–6.

- 347 14. Shrestha AC, Flower RLP, Seed CR, Rajkarnikar M, Shrestha SK, Thapa U, et al.
348 Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in
349 Nepal. *BMC Infect Dis*. 2016 Nov 25;16(1):707.
- 350 15. Andrews JR, Vaidya K, Saha S, Yousafzai MT, Hemlock C, Longley A, et al.
351 Healthcare Utilization Patterns for Acute Febrile Illness in Bangladesh, Nepal, and
352 Pakistan: Results from the Surveillance for Enteric Fever in Asia Project. *Clinical*
353 *Infectious Diseases*. 2020 Nov 1;71(Supplement_3):S248–56.
- 354 16. Hens N, Shkedy Z, Aerts M, Faes C, Van Damme P, Beutels P. Modeling infectious
355 disease parameters based on serological and social contact data: a modern statistical
356 perspective. Vol. 63. Springer Science & Business Media; 2012.
- 357 17. Wood SN. Generalized additive models: an introduction with R. Chapman and
358 Hall/CRC; 2006.
- 359 18. Marra G, Wood SN. Coverage properties of confidence intervals for generalized
360 additive model components. *Scandinavian Journal of Statistics*. 2012;39(1):53–74.
- 361 19. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using
362 lme4. *Journal of Statistical Software*. 2015 Oct 7;67:1–48.
- 363 20. Clayson ET, Shrestha MP, Vaughn DW, Snitbhan R, Shrestha KB, Longer CF, et al.
364 Rates of hepatitis E virus infection and disease among adolescents and adults in
365 Kathmandu, Nepal. *J Infect Dis*. 1997 Sep;176(3):763–6.
- 366 21. Owada K, Sarkar J, Rahman MK, Khan SA, Islam A, Hassan MM, et al.
367 Epidemiological Profile of a Human Hepatitis E Virus Outbreak in 2018, Chattogram,
368 Bangladesh. *Trop Med Infect Dis*. 2022 Aug 6;7(8):170.
- 369 22. Lenglet A, Ehlkes L, Taylor D, Fesselet JF, Nassariman JN, Ahamat A, et al. Does
370 community-wide water chlorination reduce hepatitis E virus infections during an
371 outbreak? A geospatial analysis of data from an outbreak in Am Timan, Chad (2016–
372 2017). *Journal of Water and Health*. 2020 Jun 2;18(4):556–65.
- 373 23. Takuissu GR, Kenmoe S, Ndip L, Ebogo-Belobo JT, Kengne-Ndé C, Mbaga DS, et
374 al. Hepatitis E Virus in Water Environments: A Systematic Review and Meta-analysis.
375 *Food Environ Virol*. 2022 Sep 1;14(3):223–35.
- 376 24. Hartl J, Otto B, Madden RG, Webb G, Woolson KL, Kriston L, et al. Hepatitis E
377 Seroprevalence in Europe: A Meta-Analysis. *Viruses*. 2016 Aug;8(8):211.
- 378 25. Teunis PFM, van Eijkeren JCH, de Graaf WF, Marinović AB, Kretzschmar MEE.
379 Linking the seroresponse to infection to within-host heterogeneity in antibody
380 production. *Epidemics*. 2016 Sep;16:33–9.

- 381 26. Øverbø J, Aziz A, Zaman K, Julin CH, Qadri F, Stene-Johansen K, et al. Stability and
382 Feasibility of Dried Blood Spots for Hepatitis E Virus Serology in a Rural Setting.
383 Viruses. 2022 Nov;14(11):2525.